Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $6.7 million.

  • Apellis Pharmaceuticals' Gains from Investment Securities rose 308488.89% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 7766.29%. This contributed to the annual value of $8.0 million for FY2024, which is 710.99% down from last year.
  • Apellis Pharmaceuticals' Gains from Investment Securities amounted to $6.7 million in Q3 2025, which was up 308488.89% from -$61000.0 recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Gains from Investment Securities peaked at $9.2 million during Q2 2021, and registered a low of -$15.6 million during Q1 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' median Gains from Investment Securities value was -$98000.0 (recorded in 2024), while the average stood at -$560842.1.
  • Over the last 5 years, Apellis Pharmaceuticals' Gains from Investment Securities had its largest YoY gain of 67130000.0% in 2021, and its largest YoY loss of 269695.65% in 2021.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Gains from Investment Securities stood at $8.8 million in 2021, then plummeted by 118.18% to -$1.6 million in 2022, then surged by 293.83% to $3.1 million in 2023, then plummeted by 125.27% to -$786000.0 in 2024, then soared by 954.45% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, -$61000.0 for Q2 2025, and -$198000.0 during Q1 2025.